KBC Group NV Sells 13,969 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

KBC Group NV lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 11.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 109,086 shares of the biotechnology company's stock after selling 13,969 shares during the period. KBC Group NV owned approximately 0.24% of United Therapeutics worth $33,628,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of UTHR. Dunhill Financial LLC raised its position in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at $49,000. State of Wyoming acquired a new position in shares of United Therapeutics during the 4th quarter worth $62,000. Curat Global LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth $63,000. Finally, Millstone Evans Group LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $67,000. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,681 shares of company stock worth $23,951,939. Company insiders own 10.30% of the company's stock.

United Therapeutics Trading Down 0.2%

NASDAQ:UTHR traded down $0.65 during trading hours on Thursday, hitting $294.57. 284,212 shares of the company were exchanged, compared to its average volume of 445,045. The stock has a market capitalization of $13.29 billion, a price-to-earnings ratio of 11.75, a price-to-earnings-growth ratio of 6.37 and a beta of 0.53. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The company has a fifty day simple moving average of $301.18 and a 200 day simple moving average of $323.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm's revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $6.17 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley lifted their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $386.15.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.